Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-DFC413
- Development stage
- Phase 1
- Lead developer
- Novartis
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
68Ga-DFC413 (also known as JFI447) is a Gallium-68 labeled radiopharmaceutical imaging agent developed by Novartis. It is designed to target Fibroblast Activation Protein (FAP), which is highly expressed on cancer-associated fibroblasts (CAFs) within the tumor stroma of various solid malignancies. As a Positron Emission Tomography (PET) tracer, 68Ga-DFC413 enables the non-invasive visualization and quantification of FAP expression, which is often associated with aggressive tumor behavior and poor prognosis. The agent is currently being evaluated in Phase I clinical trials (e.g., NCT06141304) to characterize its safety, biodistribution, and pharmacokinetics, and to compare its imaging performance against other FAP-targeting tracers such as 68Ga-NNS309 (FFG233) in patients with solid tumors including pancreatic, lung, breast, and colorectal cancers.
- Other names
- [68Ga]Ga-DFC413
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on 68Ga-DFC413.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-DFC413.